Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
The Role Of Apolipoprotein E4 On Cognitive Function in Parkinson's Disease: A Longitudinal Structural MRI Study in the PPMI Cohort
EF 2025-26
Résumé
Cognitive impairment is a common, burdensome non-motor symptom (NMS) of Parkinson's Disease (PD), with about 80% of PD patients progressing into dementia within 20 years of their diagnosis. Despite its prevalence, the underlying factors leading to cognitive impairment remain poorly understood in PD. Various genetic factors have been identified as potential contributors, including Apolipoprotein E4 (APOE4). APOE4 is a well-known genetic risk factor for Alzheimer's Disease, and has been associated with worsened cognition in PD. Yet, other studies report no association, underscoring the need for further research to clarify APOE4's role in this NMS of PD. Structural magnetic resonance imaging studies have reported similar gray matter (GM) changes in both patients with PD-related cognitive impairment and APOE4 carriers, including changes in GM measures such as gray matter volume (GMV) and cortical thickness (CTh) in cognitively-related brain regions. Yet, no study has comprehensively examined APOE4's impact on GM structure and their relation to cognition across the course of PD. Thus, this proposed longitudinal study aims to clarify APOE4's role on cognitive function in PD by examining its impact on GM structure using data from the Parkinson's Progression Markers Initiative. By comparing PD APOE4 carriers and non-carriers, we will: (1) evaluate APOE4's impact on widely studied (GMV and CTh) and less studied GM measures (surface area, gyrification, and curvature) to provide a comprehensive evaluation of GM changes over disease progression; and (2) determine how APOE4-related GM changes are associated to cognitive decline during PD progression. Achieving these objectives will (1) generate new knowledge on APOE4's role in cognitive function in PD through brain imaging; (2) inform the potential relevance of genetic testing to identify those at risk for this NMS at an early stage; and (3) help advance personalized medicine in PD to slow or prevent cognitive impairment.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559743
Name
Rosal Angenelle Eve
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
The Role Of Apolipoprotein E4 On Cognitive Function in Parkinson's Disease: A Longitudinal Structural MRI Study in the PPMI Cohort
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Apolipoprotein E4; Brain Biomarkers; Cognitive Impairment; Genetics; Gray Matter; Longitudinal Neuroimaging; Magnetic Resonance Imaging; Neurodegeneration; Parkinson'S Disease; Surface-Based Morphometry
Abstract
Cognitive impairment is a common, burdensome non-motor symptom (NMS) of Parkinson's Disease (PD), with about 80% of PD patients progressing into dementia within 20 years of their diagnosis. Despite its prevalence, the underlying factors leading to cognitive impairment remain poorly understood in PD. Various genetic factors have been identified as potential contributors, including Apolipoprotein E4 (APOE4). APOE4 is a well-known genetic risk factor for Alzheimer's Disease, and has been associated with worsened cognition in PD. Yet, other studies report no association, underscoring the need for further research to clarify APOE4's role in this NMS of PD. Structural magnetic resonance imaging studies have reported similar gray matter (GM) changes in both patients with PD-related cognitive impairment and APOE4 carriers, including changes in GM measures such as gray matter volume (GMV) and cortical thickness (CTh) in cognitively-related brain regions. Yet, no study has comprehensively examined APOE4's impact on GM structure and their relation to cognition across the course of PD. Thus, this proposed longitudinal study aims to clarify APOE4's role on cognitive function in PD by examining its impact on GM structure using data from the Parkinson's Progression Markers Initiative. By comparing PD APOE4 carriers and non-carriers, we will: (1) evaluate APOE4's impact on widely studied (GMV and CTh) and less studied GM measures (surface area, gyrification, and curvature) to provide a comprehensive evaluation of GM changes over disease progression; and (2) determine how APOE4-related GM changes are associated to cognitive decline during PD progression. Achieving these objectives will (1) generate new knowledge on APOE4's role in cognitive function in PD through brain imaging; (2) inform the potential relevance of genetic testing to identify those at risk for this NMS at an early stage; and (3) help advance personalized medicine in PD to slow or prevent cognitive impairment.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rosal, Angenelle Eve
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~